RE: RE: Promising RNS,,,,,9 Jul 2019 14:22
Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
Proof of Concept Now Established in Animal Models Across Key Enterobacteriaceae Indications
Pathogen-Targeted Approach Seeks to Preserve Patients’ Microbiomes
Oxford, UK, and Cambridge, MA, US, 9 July 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announces that it has demonstrated the potential of its DDS-04 series of new class antibiotics as an Enterobacteriaceae-targeted treatment through in vivo proof of concept data in sepsis and pneumonia animal models. These data build on the previously published proof of concept preclinical study for DDS-04 in urinary tract infections. Enterobacteriaceae are a family of Gram-negative bacteria that cause severe and often deadly infections.
more here.. https://www.globenewswire.com/news-release/2019/07/09/1880014/0/en/Summit-s-DDS-04-Enterobacteriaceae-Programme-Demonstrates-In-Vivo-Efficacy-in-Sepsis-and-Pneumonia.html